Researchers find important biomarker in Iressa research

Cancer researchers at Cedars-Sinai say they've found an important biomarker among the small group of patients that respond to gefitinib, or Iressa. A protein called EMP-1 is present among the patients who don't respond. Researchers have been working on finding out why a group of patients respond to Iressa while others receive no benefit. These molecular clues are considered key to determining better who would benefit from the treatment.

- read this article from Medical News Today for more

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.